Zimmer Announces Expiration of Deferred Prosecution Agreement

WARSAW, Ind., March 30 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE:
ZMH; SWX: ZMH), a leader in the orthopaedic industry, today announced that
the Deferred Prosecution Agreement (DPA) with the United States Attorney's
Office for the District of New Jersey had expired as scheduled. The Company
will no longer be subject to oversight by the monitor appointed under the DPA.

During the past 18 months, the Company has complied fully with the letter and
spirit of the DPA and has made significant enhancements to its compliance
structure and processes. The Company's enhanced corporate compliance program
addresses how the Company is to interact with physician collaborators,
managing potential or perceived conflicts of interest inherent in consulting
relationships while preserving the best elements of collaboration that drive
innovation in medical devices and services.

"While the expiration of the DPA is an important milestone, the Company
remains committed to operating ethically and transparently on a global basis
to preserve the trust required for productive, professional collaboration that
ultimately benefits patients," said David Dvorak, Zimmer President and CEO.

The Company expects to remain subject to the terms of a Corporate Integrity
Agreement it entered into with the Office of Inspector General of the
Department of Health and Human Services until September 2012.

About Zimmer Holdings, Inc.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs,
develops, manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical products. Zimmer has
operations in more than 25 countries around the world and sells products in
more than 100 countries. Zimmer's 2008 sales were approximately $4.1 billion.
The Company is supported by the efforts of approximately 8,500 employees
worldwide.

For more information about Zimmer, visit www.zimmer.com

Zimmer Safe Harbor Statement
This press release contains forward-looking statements within the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995 based on
current expectations, estimates, forecasts and projections about the
orthopaedics industry, management's beliefs and assumptions made by
management. Forward-looking statements may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "assumes," "guides,"
"targets," "forecasts," and "seeks" or the negative of such terms or other
variations on such terms or comparable terminology. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that could cause actual outcomes and results to differ materially.
For a list and description of such risks and uncertainties, see our periodic
reports filed with the U.S. Securities and Exchange Commission. We disclaim
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise, except as may be set forth in our periodic reports. Readers of
this document are cautioned not to place undue reliance on these
forward-looking statements, since, while we believe the assumptions on which
the forward-looking statements are based are reasonable, there can be no
assurance that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

SOURCE Zimmer Holdings, Inc.

Media: Brad Bishop, +1-574-372-4291, bradley.bishop@zimmer.com, Investors:
Paul Blair, +1-574-371-8042, paul.blair@zimmer.com, or James T. Crines,
+1-574-372-4264, james.crines@zimmer.com, all for Zimmer Holdings, Inc.